Ftse Mib
33.494,83
0,60%
DAX
19.322,59
0,91%
S&P 500
5.969,34
0,35%
NASDAQ
19.003,65
0,16%
Bitcoin
98.912,76
-0,12%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Aclaris Therapeutics Inc (ACRS) Aclaris Therapeutics Inc (ACRS) Notizie

ACRS

Aclaris Therapeutics (ACRS)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ACRS
DataOraFonteTitoloSimboloCompagnia
22/11/202422:00Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ACRSAclaris Therapeutics Inc
20/11/202422:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
19/11/202422:05AllPennyStocks.comThis Healthcare Stock Soared Following Exclusive License Agreement AnnouncementNASDAQ:ACRSAclaris Therapeutics Inc
18/11/202422:20Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
18/11/202414:50PR Newswire (US)Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology AssetsNASDAQ:ACRSAclaris Therapeutics Inc
18/11/202414:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRSAclaris Therapeutics Inc
18/11/202414:10GlobeNewswire Inc.Aclaris Therapeutics Announces $80 Million Private PlacementNASDAQ:ACRSAclaris Therapeutics Inc
18/11/202414:10GlobeNewswire Inc.Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to PipelineNASDAQ:ACRSAclaris Therapeutics Inc
06/11/202422:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACRSAclaris Therapeutics Inc
06/11/202413:00GlobeNewswire Inc.Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
17/09/202413:00GlobeNewswire Inc.Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic DermatitisNASDAQ:ACRSAclaris Therapeutics Inc
10/09/202413:00GlobeNewswire Inc.Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare ConferenceNASDAQ:ACRSAclaris Therapeutics Inc
07/08/202413:00GlobeNewswire Inc.Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
16/07/202422:01GlobeNewswire Inc.Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 MillionNASDAQ:ACRSAclaris Therapeutics Inc
06/06/202413:00GlobeNewswire Inc.Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:ACRSAclaris Therapeutics Inc
07/05/202422:06Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ACRSAclaris Therapeutics Inc
07/05/202422:01GlobeNewswire Inc.Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
30/04/202413:00GlobeNewswire Inc.Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
23/04/202414:00PR Newswire (US)Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive OfficerNASDAQ:ACRSAclaris Therapeutics Inc
27/02/202413:30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ACRSAclaris Therapeutics Inc
27/02/202413:00GlobeNewswire Inc.Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
15/02/202402:32Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ACRSAclaris Therapeutics Inc
05/02/202422:31Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ACRSAclaris Therapeutics Inc
16/01/202413:00GlobeNewswire Inc.Aclaris Therapeutics Announces Leadership Changes and Strategic Business ReviewNASDAQ:ACRSAclaris Therapeutics Inc
10/01/202413:00GlobeNewswire Inc.Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic DermatitisNASDAQ:ACRSAclaris Therapeutics Inc
19/12/202322:01GlobeNewswire Inc.Aclaris Therapeutics Provides Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
05/12/202322:01GlobeNewswire Inc.Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for AlopeciaNASDAQ:ACRSAclaris Therapeutics Inc
13/11/202313:00GlobeNewswire Inc.Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
06/11/202313:00GlobeNewswire Inc.Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
23/10/202322:06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ACRS

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
ENEL
Enel
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
STMMI
ST Microelectronics
BIT
RACE
Ferrari NV
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
BPE
Bper Banca
BIT
SPM
Saipem
BIT
BAMI
Banco BPM
BIT
TEN
Tenaris
BIT
MONC
Moncler
BIT
LDO
Leonardo
BIT
CPR
Davide Campari
BIT
PRY
Prysmian
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network